SEARCH

SEARCH BY CITATION

References

  • 1
    Levine B., Kalman J., Mayer L., et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236241.
  • 2
    McMurray J., Abdullah I., Dargie HJ, Shapiro D. Increased concentrations of tumour necrosis factor in “cachectic” patients with severe chronic heart failure. Br Heart J 1991;66:356358.
  • 3
    Freeman LM, Rush JE, Kehayias JJ, et al. Nutritional alterations and the effect of fish oil supplementation in dogs with heart failure. J Vet Intern Med 1998;12:440448.
  • 4
    Meurs KM, Fox PR, Miller MW, et al. Plasma concentrations of tumor necrosis factor-alpha in cats with congestive heart failure. Am J Vet Res 2002;63:640642.
  • 5
    Acanfora D., Gheorghiade M., Trojano L., et al. Relative lymphocyte count: A prognostic indicator of mortality in elderly patients with congestive heart failure. Am Heart J 2001;142:167173.
  • 6
    Anand I., Florea V., Glazer R., et al. Baseline percent lymphocyte count and changes in percent lymphocyte count over time and subsequent mortality and morbidity in Val-HeFT. J Cardiac Failure 2002; 8(Suppl):S54.
  • 7
    Ommen SR, Hodge DO, Rodeheffer RJ, et al. Predictive power of the relative lymphocyte concentration in patients with advanced heart failure. Circulation 1998;97:1922.
  • 8
    Yokoi M., Sawada T., Yamano T., et al. Relationship between lymphocyte count and long-term outcome in patients with dilated car-diomyopathy presenting in acute progressive heart failure. J Cardiac Failure 1999;5:69.
  • 9
    Hwang S., Harris TJ, Wilson NW, Maisel AS. Immune function in patients with chronic stable congestive heart failure. Am Heart J 1993;125:16511658.
  • 10
    Fowles RE, Bieber CP, Stinson EB. Defective in vitro suppressor cell function in idiopathic congestive cardiomyopathy. Circ 1979; 59:483491.
  • 11
    Eckstein R., Mempel W., Bolte HD. Reduced suppressor cell activity in congestive cardiomyopathy and in myocarditis. Circ 1982; 65:12241229.
  • 12
    Sanderson JE, Koech D., Iha D., et al. T-lymphocyte subsets in idiopathic cardiomyopathy. Am J Cardiol 1985;55:755758.
  • 13
    Franceschini R., Messina V., Petillo A., et al. Humoral immunity and lymphocyte subpopulations in patients with dilated cardiomyop-athy. Int J Cardiol 1985;8:113123.
  • 14
    Takamoto T., Hori Y., Yokoyama M., et al. Lymphocyte subsets in patients with dilated cardiomyopathy and perimyocarditis. J Clin Lab Immunol 1986;19:113116.
  • 15
    Huber KC, Gersh BJ, Sugrue DD, et al. T-lymphocyte subsets in patients with idiopathic cardiomyopathy. Arch Immunol Ther Exp 1991;39:3340.
  • 16
    Maisel AS, Knowlton KU, Fowler P., et al. Adrenergic control of circulating lymphocyte subpopulations. Effects of congestive heart failure, dynamic exercise, and terbutaline treatment. J Clin Inv 1990; 85: 462467.
  • 17
    Kanda T., Yokoyama T., Ohshima S., et al. T-lymphocyte subsets as noninvasive markers of cardiomyopathy. Clin Cardiol 1990;13:617622.
  • 18
    Maruta M., Takenaka K., Takabe H., et al. Humoral immunity and lymphocyte subsets in patients with dilated cardiomyopathy. Japan J Clin Pathol 1991;39:824828.
  • 19
    Smalcelj A., Durakovic Z., Batinic D., et al. Relation between helper and suppressive/cytotoxic T lymphocytes in the peripheral blood in patients with dilated cardiomyopathy. Acta Med Yugoslavica 1991;45:313.
  • 20
    Bozkurt A., Canataroglu A., Cetiner S., et al. Lymphocyte subsets in patients with idiopathic dilated cardiomyopathy. Ana Kar Der 2001; 1:98100.
  • 21
    Koga Y., Miyazaki Y., Toshima H., et al. Lymphocyte subsets in patients with acute myopericarditis, arrhythmias and dilated cardio-myopathy. Jpn Circ J 1989;53:7886.
  • 22
    Yamakawa K., Fukuta S., Yoshinaga T., et al. Study on lymphocyte subsets and NK cell function in patients with dilated cardiomy-opathy. Jpn Circ J 1986;50:12591263.
  • 23
    Grzelak I., Lukomska B., Sadowsky-Szablisty D., et al. Immu-nophenotypic and functional characterization of peripheral blood mononuclear cell populations in patients with dilated cardiomyopathy. Arch Immunol Ther Exp 1991;39:330340.
  • 24
    Anderson JL, Carlquist JF, Higashikubo R. Quantification of lymphocyte subsets by immunofluorescence flow cytometry in idio-pathic dilated cardiomyopathy. Am J Cardiol 1985;55:15501554.
  • 25
    Borgarelli M., Zini E., D'Agnolo G., et al. A retrospective review of the clinical presentation, survival, and lymphocytic immunotype in German Shepherds with primary mitral insufficiency. Proceedings of the 20th Annual ACVIM Forum, Dallas TX, 2002: 106107.
  • 26
    Klappacher G., Mehrabi M., Plesch K., et al. Serum-soluble CD4 as clinical and immunological marker in patients with dilated cardio-myopathy. Immunol Lett 1993;38:103109.
  • 27
    Kyne L., Hausdorff J., Knight E., et al. Neutrophilia and congestive heart failure after acute myocardial infarction. Am Heart J 2000; 139:94100.
  • 28
    Horwich TB, Fonarow GC, Hamilton MA, et al. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 2002;39:17801786.
  • 29
    Kosiborod M., Smith GL, Radford MJ, et al. The prognostic importance of anemia in patients with heart failure. Am J Med 2003; 114:112119.
  • 30
    Tanner H., Moschovitis G., Kuster G., et al. The prevalence of anemia in chronic heart failure. Int J Cardiol 2002;86:115121.
  • 31
    Mozaffarian D., Nye R., Levy W. Anemia predicts mortality in severe heart failure. The prospective randomized amlodipine survival evaluation (PRAISE). J Am Coll Cardiol 2003; 41: 19331939.
  • 32
    McClellan W., Flanders W., Langston R., et al. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population based study. J Am Soc Nephrol 2002;13:19281936.
  • 33
    Ezekowitz J., McAlister F., Armstrong P. Anemia is common in heart failure and is associated with poor outcome: Insights from a cohort of 12,065 patients with new-onset heart failure. Circulation 2003;107:223225.
  • 34
    Stevenson J., Westermann J., Liebmann P., et al. Prolonged alpha-adrenergic stimulation causes changes in leukocyte distribution and lymphocyte apoptosis in the rat. J Neuroimmunol 2001;120:5057.
  • 35
    Silverberg D., Wexler D., Sheps D., et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001;37:17751780.
  • 36
    Olsen LH, Kristensen AT, Haggstrom J., et al. Increased platelet aggregation response in Cavalier King Charles Spaniels with mitral valve prolapse. J Vet Intern Med 2001;15:209216.
  • 37
    Smedile LE, Houston DM, Taylor SM, et al. Idiopathic, asymptomatic thrombocytopenia in Cavalier King Charles spaniels: 11 cases (1983–1983). J Am Anim Hosp Assoc 1997; 33: 411415.
  • 38
    Pedersen HD, Haggstrom J., Olsen LH, et al. Idiopathic asymptomatic thrombocytopenia in Cavalier King Charles Spaniels is an au-tosomal recessive trait. J Vet Intern Med 2002;16:169173.
  • 39
    Tanaka R., Yamane Y. Platelet aggregation in dogs with mitral valve regurgitation. Am J Vet Res 2000;61:12481251.
  • 40
    Moore PF, Rossitto PV, Danilenko DM, et al. Monoclonal antibodies specific for canine CD4 and CD8 define functional T-lym-phocyte subsets and high-density expression of CD4 by canine neu-trophils. Tissue Antigens 1992;40:7585.
  • 41
    Cobbold S., Metcalfe S. Monoclonal antibodies that define canine homologues of human CD antigens: Summary of the First International Canine Leukocyte Antigen Workshop (CLAW). Tissue Antigens 1994;43:137154.
  • 42
    Byrne KM, Kim HW, Chew BP, et al. A standardized gating technique for the generation of flow cytometry data for normal canine and normal feline blood lymphocytes. Vet Immunol Immunopathol 2000;73:167182.